A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
NCT04951635 · Phase 3 · Recruiting
PHASEPhase 3
STATUSRecruiting
ENROLLMENT150
EST. COMPLETION2024-07-15
Conditions
Interventions
Study details
SPONSORJiangsu Hansoh Pharmaceutical Co., Ltd.
START DATE2021-03-18
Related company profiles
Primary source
Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.
Evidence & limits
Source: Open the source record
- Record identifier
- NCT04951635
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.
Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.
Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.